ArticleInternational journal of genomics2026
Integrative Single-Cell and Bulk Transcriptomics Identifies a Proliferative Malignant State and Supports a Functional Contribution of TROAP in Osteosarcoma.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma contains heterogeneous malignant-cell states whose clinical relevance is difficult to infer from small single-cell cohorts. Methods: We reanalyzed six treatment-naive osteosarcomas from GSE162454, identified CNV-supported malignant osteoblastic cells, and characterized a recurrent proliferative/mitotic state using patient-paired pseudobulk analysis and program-selection sensitivity tests. A 50-gene module was evaluated for association with metastatic occurrence in 53 pretreatment tumors from GSE21257. Candidate ranking was audited across transparent weighting scenarios, and TROAP was depleted with two independent siRNAs in HOS and U2OS cells. Results: Of 52,489 input barcodes, 39,063 singlets were retained, including 10,456 CNV-supported malignant osteoblastic cells. M6 comprised 725 cells and was detected in all six tumors. It ranked first in six of eight program-selection scenarios but fell to fifth when G2M checkpoint and E2F targets were jointly excluded, supporting its interpretation as a proliferative/mitotic state. Its weighted module was higher in metastatic tumors ( Conclusion: A recurrent proliferative/mitotic malignant state is detectable across the six osteosarcomas and yields a bulk expression program associated with metastatic occurrence, although this association is sensitive to macrophage composition. TROAP is supported as a functional contributor to osteosarcoma cell phenotypes rather than an established driver of the state or an independently validated clinical marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.